{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:15:59Z","timestamp":1791569759983,"version":"4.3.4"},"reference-count":143,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT 1176538"],"award-info":[{"award-number":["GNT 1176538"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.semarthrit.2020.12.004","type":"journal-article","created":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T09:03:24Z","timestamp":1608195804000},"page":"49-71","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Management of inflammatory neurologic and psychiatric manifestations of systemic lupus erythematosus: A systematic review"],"prefix":"10.1016","volume":"51","author":[{"given":"D.A.","family":"Papachristos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Oon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.G.","family":"Hanly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Nikpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.semarthrit.2020.12.004_bib0001","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41584-018-0156-8","article-title":"Neuropsychiatric lupus: new mechanistic insights and future treatment directions","volume":"15","author":"Schwartz","year":"2019","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2020.12.004_bib0002","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/1529-0131(199904)42:4<599::AID-ANR2>3.0.CO;2-F","article-title":"The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes","volume":"42","year":"1999","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.12.004_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.semarthrit.2010.08.001","article-title":"Neuropsychiatric syndromes in systemic lupus erythematosus: a meta-analysis","volume":"41","author":"Unterman","year":"2011","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.semarthrit.2020.12.004_bib0004","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/art.23566","article-title":"Short-term outcome of neuropsychiatric events in systemic lupus erythematosus upon enrollment into an international inception cohort study","volume":"59","author":"Hanly","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.semarthrit.2020.12.004_bib0005","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1093\/rheumatology\/keu384","article-title":"Development and validation of a new algorithm for attribution of neuropsychiatric events in systemic lupus erythematosus","volume":"54","author":"Bortoluzzi","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.semarthrit.2020.12.004_bib0006","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1136\/annrheumdis-2019-216150","article-title":"Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach","volume":"79","author":"Hanly","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.semarthrit.2020.12.004_bib0007","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1007\/s10067-017-3775-6","article-title":"Mycophenolate mofetil and deflazacort combination in neuropsychiatric lupus: a decade of experience from a tertiary care teaching hospital in southern India","volume":"36","author":"Gupta","year":"2017","journal-title":"Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2020.12.004_bib0008","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1177\/0961203315622821","article-title":"Cyclophosphamide in combination with glucocorticoids for severe neuropsychiatric systemic lupus erythematosus: a retrospective, observational two-centre study","volume":"25","author":"Fanouriakis","year":"2016","journal-title":"Lupus"},{"issue":"9","key":"10.1016\/j.semarthrit.2020.12.004_bib0009","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1002\/art.1780370907","article-title":"Corticosteroids and neuropsychological functioning in patients with systemic lupus erythematosus","volume":"37","author":"Denburg","year":"1994","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.semarthrit.2020.12.004_bib0010","first-page":"764","article-title":"Intrathecal injection with methotrexate plus dexamethasone in the treatment of central nervous system involvement in systemic lupus erythematosus","volume":"114","author":"Dong","year":"2001","journal-title":"Chin Med J (Engl)"},{"issue":"10","key":"10.1016\/j.semarthrit.2020.12.004_bib0011","first-page":"681","article-title":"Central nervous system involvement in systemic lupus erythematosus","volume":"38","author":"Zhang","year":"1999","journal-title":"Zhonghua Nei Ke Za Zhi"},{"issue":"7","key":"10.1016\/j.semarthrit.2020.12.004_bib0012","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s00330-003-2166-3","article-title":"Evaluation of the effects of methylprednisolone pulse therapy in patients with systemic lupus erythematosus with brain involvement by Tc-99m HMPAO brain SPECT","volume":"14","author":"Sun","year":"2004","journal-title":"Eur Radiol"},{"issue":"4","key":"10.1016\/j.semarthrit.2020.12.004_bib0013","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s00296-002-0282-z","article-title":"Usefulness of Tc-99m ECD brain SPECT to evaluate the effects of methylprednisolone pulse therapy in lupus erythematosus with brain involvement: a preliminary report","volume":"23","author":"Liu","year":"2003","journal-title":"Rheumatol Int"},{"issue":"3","key":"10.1016\/j.semarthrit.2020.12.004_bib0014","first-page":"179","article-title":"Neuropsychiatric manifestations in Thai patients with systemic lupus erythematosus","volume":"20","author":"Kasitanon","year":"2002","journal-title":"Asian Pac J Allergy Immunol"},{"issue":"9","key":"10.1016\/j.semarthrit.2020.12.004_bib0015","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1007\/s00296-011-2053-1","article-title":"Initial presentation of acute transverse myelitis in systemic lupus erythematosus: demographics, diagnosis, management and comparison to idiopathic cases","volume":"32","author":"Schulz","year":"2012","journal-title":"Rheumatol Int"},{"issue":"2","key":"10.1016\/j.semarthrit.2020.12.004_bib0016","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/j.1755-3768.2008.01193.x","article-title":"Systemic lupus erythematosus-associated optic neuritis: clinical experience and literature review","volume":"87","author":"Lin","year":"2009","journal-title":"Acta Ophthalmol"},{"issue":"4","key":"10.1016\/j.semarthrit.2020.12.004_bib0017","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1177\/096120339600500409","article-title":"Transverse myelopathy in SLE: clinical features and functional outcomes","volume":"5","author":"Chan","year":"1996","journal-title":"Lupus"},{"issue":"4","key":"10.1016\/j.semarthrit.2020.12.004_bib0018","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1046\/j.1442-9071.2001.00424.x","article-title":"Neuro-ophthalmological manifestations of systemic lupus erythematosus in Asian patients","volume":"29","author":"Teoh","year":"2001","journal-title":"Clin Exp Ophthalmol"},{"issue":"5","key":"10.1016\/j.semarthrit.2020.12.004_bib0019","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/BF00878876","article-title":"Lupus transverse myelopathy: better outcome with early recognition and aggressive high-dose intravenous corticosteroid pulse treatment","volume":"242","author":"Harisdangkul","year":"1995","journal-title":"J Neurol"},{"issue":"4","key":"10.1016\/j.semarthrit.2020.12.004_bib0020","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/art.1780340408","article-title":"Magnetic resonance imaging of central nervous system lesions in patients with lupus erythematosus. Correlation with clinical remission and antineurofilament and anticardiolipin antibody titers","volume":"34","author":"Bell","year":"1991","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.semarthrit.2020.12.004_bib0021","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/00041327-200109000-00006","article-title":"Optic neuropathy and chiasmopathy in the diagnosis of systemic lupus erythematosus","volume":"21","author":"Siatkowski","year":"2001","journal-title":"J Neuroophthalmol"},{"issue":"5","key":"10.1016\/j.semarthrit.2020.12.004_bib0022","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1191\/0961203302lu205oa","article-title":"Oculomotor palsy in six patients with systemic lupus erythematosus. A possible role of antiphospholipid syndrome","volume":"11","author":"Genevay","year":"2002","journal-title":"Lupus"},{"issue":"13","key":"10.1016\/j.semarthrit.2020.12.004_bib0023","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1002\/mds.23863","article-title":"Long-term outcome of 32 patients with chorea and systemic lupus erythematosus or antiphospholipid antibodies","volume":"26","author":"Reiner","year":"2011","journal-title":"Mov Disord"},{"issue":"4","key":"10.1016\/j.semarthrit.2020.12.004_bib0024","first-page":"389","article-title":"Spinal cord involvement and systemic lupus erythematosus: clinical and magnetic resonance findings in 5 patients","volume":"12","author":"Salmaggi","year":"1994","journal-title":"Clin Exp Rheumatol"},{"issue":"12","key":"10.1016\/j.semarthrit.2020.12.004_bib0025","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1136\/jnnp.55.12.1157","article-title":"Neuropsychiatric systemic lupus erythematosus in elderly people: a case series","volume":"55","author":"Dennis","year":"1992","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.1016\/j.semarthrit.2020.12.004_bib0026","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1136\/ard.2004.025528","article-title":"Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus","volume":"64","author":"Barile-Fabris","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.12.004_bib0027","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1191\/0961203303lu251oa","article-title":"Neuropsychiatric lupus favourable response to low dose i.v. cyclophosphamide and prednisolone (pilot study)","volume":"12","author":"Stojanovich","year":"2003","journal-title":"Lupus"},{"issue":"5","key":"10.1016\/j.semarthrit.2020.12.004_bib0028","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1002\/art.27371","article-title":"High-dose cyclophosphamide versus monthly intravenous cyclophosphamide for systemic lupus erythematosus: a prospective randomized trial","volume":"62","author":"Petri","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.12.004_bib0029","first-page":"101","article-title":"Intermittent intravenous pulse cyclophosphamide treatment in systemic lupus erythematosus","volume":"96","author":"Malaviya","year":"1992","journal-title":"Indian J Med Res"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.12.004_bib0030","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0002-9343(03)00135-9","article-title":"Treatment of lupus psychosis with oral cyclophosphamide followed by azathioprine maintenance: an open-label study","volume":"115","author":"Mok","year":"2003","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.12.004_bib0031","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0002-9343(98)00372-6","article-title":"Cyclophosphamide pulse therapy in optic neuritis due to systemic lupus erythematosus: an open trial","volume":"106","author":"Galindo-Rodr\u00edguez","year":"1999","journal-title":"Am J Med"},{"issue":"296","key":"10.1016\/j.semarthrit.2020.12.004_bib0032","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/qjmed\/81.3.975","article-title":"Pulse cyclophosphamide for severe neuropsychiatric lupus","volume":"81","author":"Boumpas","year":"1991","journal-title":"Q J Med"},{"key":"10.1016\/j.semarthrit.2020.12.004_bib0033","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/540738","article-title":"Clinical Characteristics of Cerebral Venous Sinus Thrombosis in Patients with Systemic Lupus Erythematosus: a Single-Centre Experience in China","volume":"2015","author":"Wang","year":"2015","journal-title":"J Immunol Res"},{"issue":"3","key":"10.1016\/j.semarthrit.2020.12.004_bib0034","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1177\/0961203316659152","article-title":"Myelitis in systemic lupus erythematosus: clinical characteristics and effect in accrual damage. A single-center experience","volume":"26","author":"Quintanilla-Gonz\u00e1lez","year":"2017","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.12.004_bib0035","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0002-9343(99)80078-3","article-title":"Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus","volume":"98","author":"Neuwelt","year":"1995","journal-title":"Am J Med"},{"issue":"3","key":"10.1016\/j.semarthrit.2020.12.004_bib0036","first-page":"295","article-title":"Pulse cyclophosphamide in the treatment of neuropsychiatric systemic lupus erythematosus","volume":"14","author":"Ramos","year":"1996","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.12.004_bib0037","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1177\/0961203314547795","article-title":"Systemic lupus erythematosus-associated acute transverse myelitis: manifestations, treatments, outcomes, and prognostic factors in 20 patients","volume":"24","author":"Saison","year":"2015","journal-title":"Lupus"},{"issue":"2","key":"10.1016\/j.semarthrit.2020.12.004_bib0038","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1136\/ard.59.2.120","article-title":"Transverse myelopathy in systemic lupus erythematosus: an analysis of 14 cases and review of the literature","volume":"59","author":"Kovacs","year":"2000","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.semarthrit.2020.12.004_bib0039","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1136\/ard.56.8.481","article-title":"Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide","volume":"56","author":"Martin-Suarez","year":"1997","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.semarthrit.2020.12.004_bib0040","first-page":"370","article-title":"Transverse myelitis in systemic lupus erythematosus\u2013the effect of IV pulse methylprednisolone and cyclophosphamide","volume":"19","author":"Barile","year":"1992","journal-title":"J Rheumatol"},{"issue":"12","key":"10.1016\/j.semarthrit.2020.12.004_bib0041","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1191\/096120301701548490","article-title":"Longitudinal myelitis associated with systemic lupus erythematosus: clinical features and magnetic resonance imaging of six cases","volume":"10","author":"T\u00e9llez-Zenteno","year":"2001","journal-title":"Lupus"},{"key":"10.1016\/j.semarthrit.2020.12.004_bib0042","doi-asserted-by":"crossref","first-page":"16005","DOI":"10.1038\/scsandc.2016.5","article-title":"Myelitis in systemic lupus erythematosus: clinical features, immunological profile and magnetic resonance imaging of five cases","volume":"2","author":"Hryb","year":"2016","journal-title":"Spinal Cord Ser Cases"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.12.004_bib0043","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/art.25052","article-title":"Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial","volume":"62","author":"Ginzler","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.semarthrit.2020.12.004_bib0044","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3899\/jrheum.150779","article-title":"Mycophenolate Mofetil in Nonrenal Manifestations of Systemic Lupus Erythematosus: an Observational Cohort Study","volume":"43","author":"Tselios","year":"2016","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.12.004_bib0045","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.semarthrit.2015.02.008","article-title":"Mycophenolate mofetil in primary central nervous system vasculitis","volume":"45","author":"Salvarani","year":"2015","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.semarthrit.2020.12.004_bib0046","first-page":"397","article-title":"Cyclosporine A in the long-term management of systemic lupus erythematosus","volume":"25","author":"Germano","year":"2011","journal-title":"J Biol Regul Homeost Agents"},{"issue":"2","key":"10.1016\/j.semarthrit.2020.12.004_bib0047","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1007\/s12013-014-0010-9","article-title":"Impact analysis of autoantibody level and NR2 antibody level in neuropsychiatric SLE treated by methylprednisolone combined with MTX and DXM intrathecal injection","volume":"70","author":"Wang","year":"2014","journal-title":"Cell Biochem Biophys"},{"issue":"4","key":"10.1016\/j.semarthrit.2020.12.004_bib0048","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1136\/ard.2006.057885","article-title":"Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system","volume":"66","author":"Tokunaga","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.semarthrit.2020.12.004_bib0049","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3109\/s10165-007-0565-z","article-title":"A multicenter phase I\/II trial of rituximab for refractory systemic lupus erythematosus","volume":"17","author":"Tanaka","year":"2007","journal-title":"Mod Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2020.12.004_bib0050","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/rheumatology\/keh443","article-title":"Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab","volume":"44","author":"Tokunaga","year":"2005","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.semarthrit.2020.12.004_bib0051","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1177\/0961203317749047","article-title":"Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus","volume":"27","author":"Iwata","year":"2018","journal-title":"Lupus"},{"issue":"10","key":"10.1016\/j.semarthrit.2020.12.004_bib0052","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1002\/art.30466","article-title":"B cell biomarkers of rituximab responses in systemic lupus erythematosus","volume":"63","author":"Vital","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.semarthrit.2020.12.004_bib0053","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1177\/0961203311409273","article-title":"Rituximab induces a rapid and sustained remission in Colombian patients with severe and refractory systemic lupus erythematosus","volume":"20","author":"Pinto","year":"2011","journal-title":"Lupus"},{"issue":"10","key":"10.1016\/j.semarthrit.2020.12.004_bib0054","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1177\/0961203312446627","article-title":"Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study","volume":"21","author":"Fern\u00e1ndez-Nebro","year":"2012","journal-title":"Lupus"},{"issue":"4","key":"10.1016\/j.semarthrit.2020.12.004_bib0055","first-page":"468","article-title":"Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases","volume":"28","author":"Ramos-Casals","year":"2010","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2020.12.004_bib0056","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/art.24341","article-title":"A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients","volume":"61","author":"Lu","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.semarthrit.2020.12.004_bib0057","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1002\/art.22046","article-title":"Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment","volume":"54","author":"Smith","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.semarthrit.2020.12.004_bib0058","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s10067-011-1714-5","article-title":"Rituximab in the treatment of severe lupus myelopathy","volume":"30","author":"Ye","year":"2011","journal-title":"Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2020.12.004_bib0059","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s10067-014-2839-0","article-title":"The efficacy and safety of rituximab in a chart review study of 15 patients with systemic lupus erythematosus","volume":"34","author":"Hickman","year":"2015","journal-title":"Clin Rheumatol"},{"issue":"11","key":"10.1016\/j.semarthrit.2020.12.004_bib0060","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1136\/annrheumdis-2011-200831","article-title":"Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials","volume":"71","author":"Manzi","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.semarthrit.2020.12.004_bib0061","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.3899\/jrheum.150470","article-title":"Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices","volume":"42","author":"Hui-Yuen","year":"2015","journal-title":"J Rheumatol"},{"issue":"11","key":"10.1016\/j.semarthrit.2020.12.004_bib0062","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1046\/j.1525-1594.2000.06623.x","article-title":"Cyclosporin A and therapeutic plasma exchange in the treatment of severe systemic lupus erythematosus","volume":"24","author":"Bambauer","year":"2000","journal-title":"Artif Organs"},{"issue":"2","key":"10.1016\/j.semarthrit.2020.12.004_bib0063","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1046\/j.1526-0968.2003.00032.x","article-title":"The role of plasmapheresis in the treatment of severe central nervous system neuropsychiatric systemic lupus erythematosus","volume":"7","author":"Neuwelt","year":"2003","journal-title":"Ther Apher Dial"},{"issue":"10","key":"10.1016\/j.semarthrit.2020.12.004_bib0064","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1177\/0961203307081840","article-title":"Adjunctive plasma exchanges to treat neuropsychiatric lupus: a retrospective study on 10 patients","volume":"16","author":"Bartolucci","year":"2007","journal-title":"Lupus"},{"key":"10.1016\/j.semarthrit.2020.12.004_bib0065","article-title":"Therapeutic Plasma Exchange as Management of Complicated Systemic Lupus Erythematosus and Other Autoimmune Diseases","volume":"2019","author":"Aguirre-Valencia","year":"2019","journal-title":"Autoimmune Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.12.004_bib0066","doi-asserted-by":"crossref","first-page":"32","DOI":"10.5152\/eurjrheum.2017.17088","article-title":"Therapeutic plasma exchange for refractory SLE: a comparison of outcomes between different sub-phenotypes","volume":"5","author":"Soyu\u00f6z","year":"2018","journal-title":"Eur J Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2020.12.004_bib0067","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1744-9987.1998.tb00120.x","article-title":"Outcome of collagen vascular diseases by treatment with plasmapheresis","volume":"2","author":"Hashimoto","year":"1998","journal-title":"Ther Apher"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.12.004_bib0068","first-page":"41","article-title":"Treatment with intravenous immunoglobulins in systemic lupus erythematosus: a series of 52 patients from a single centre","volume":"32","author":"Camara","year":"2014","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2020.12.004_bib0069","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.semarthrit.2005.08.008","article-title":"Chronic inflammatory demyelinating polyneuropathy in patients with systemic lupus erythematosus: prognosis and outcome","volume":"35","author":"Vina","year":"2005","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.semarthrit.2020.12.004_bib0070","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1001\/jama.295.5.527","article-title":"Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus","volume":"295","author":"Burt","year":"2006","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.semarthrit.2020.12.004_bib0071","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1191\/0961203304lu1027oa","article-title":"Autologous stem cell transplantation for systemic lupus erythematosus","volume":"13","author":"Jayne","year":"2004","journal-title":"Lupus"},{"issue":"3","key":"10.1016\/j.semarthrit.2020.12.004_bib0072","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1177\/0961203312470729","article-title":"Autologous haematopoietic stem cell transplantation for systemic lupus erythematosus: data from the European Group for Blood and Marrow Transplantation registry","volume":"22","author":"Alchi","year":"2013","journal-title":"Lupus"},{"issue":"12","key":"10.1016\/j.semarthrit.2020.12.004_bib0073","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1177\/0961203315585816","article-title":"Electroconvulsive therapy as a treatment for refractory neuropsychiatric lupus with catatonia: three case studies and literature review","volume":"24","author":"Bica","year":"2015","journal-title":"Lupus"},{"issue":"3","key":"10.1016\/j.semarthrit.2020.12.004_bib0074","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/YCT.0b013e3182809c01","article-title":"Electroconvulsive therapy for severe neuropsychiatric lupus with psychosis","volume":"29","author":"Tan","year":"2013","journal-title":"J ECT"},{"issue":"6","key":"10.1016\/j.semarthrit.2020.12.004_bib0075","doi-asserted-by":"crossref","first-page":"350","DOI":"10.4081\/reumatismo.2012.350","article-title":"Therapeutic strategies in severe neuropsychiatric systemic lupus erythematosus: experience from a tertiary referral centre","volume":"64","author":"Bortoluzzi","year":"2012","journal-title":"Reumatismo"},{"issue":"4","key":"10.1016\/j.semarthrit.2020.12.004_bib0076","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1177\/0961203307088005","article-title":"Prognostic factors of lupus myelopathy","volume":"17","author":"Lu","year":"2008","journal-title":"Lupus"},{"issue":"2","key":"10.1016\/j.semarthrit.2020.12.004_bib0077","first-page":"280","article-title":"Transverse myelitis as the first manifestation of systemic lupus erythematosus or lupus-like disease: good functional outcome and relevance of antiphospholipid antibodies","volume":"31","author":"D'Cruz","year":"2004","journal-title":"J Rheumatol"},{"issue":"10","key":"10.1016\/j.semarthrit.2020.12.004_bib0078","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1093\/rheumatology\/ken260","article-title":"Psychosis due to systemic lupus erythematosus: characteristics and long-term outcome of this rare manifestation of the disease","volume":"47","author":"Pego-Reigosa","year":"2008","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.semarthrit.2020.12.004_bib0079","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1177\/0961203316636473","article-title":"Epileptic syndrome in systemic lupus erythematosus and neuronal autoantibody associations","volume":"25","author":"Kampylafka","year":"2016","journal-title":"Lupus"},{"issue":"4","key":"10.1016\/j.semarthrit.2020.12.004_bib0080","doi-asserted-by":"crossref","first-page":"175","DOI":"10.4081\/reumatismo.2017.1007","article-title":"Demyelinating syndrome in SLE: review of different disease subtypes and report of a case series","volume":"69","author":"Chessa","year":"2017","journal-title":"Reumatismo"},{"issue":"7","key":"10.1016\/j.semarthrit.2020.12.004_bib0081","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1212\/01.wnl.0000267320.48939.d0","article-title":"CNS lupus: a study of 41 patients","volume":"69","author":"Joseph","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.semarthrit.2020.12.004_bib0082","article-title":"Short- and Long-Term Outcome of Systemic Lupus Erythematosus Peripheral Neuropathy: bimodal Pattern of Onset and Treatment Response","author":"Fargetti","year":"2019","journal-title":"J Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2020.12.004_bib0083","first-page":"467","article-title":"Acute transverse myelopathy in systemic lupus erythematosus: clinical presentation, treatment, and outcome","volume":"25","author":"Mok","year":"1998","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2020.12.004_bib0084","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3904\/kjim.2016.383","article-title":"Clinical features and prognoses of acute transverse myelitis in patients with systemic lupus erythematosus","volume":"34","author":"Ahn","year":"2019","journal-title":"Korean J Intern Med"},{"issue":"6","key":"10.1016\/j.semarthrit.2020.12.004_bib0085","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1007\/s00415-017-8519-7","article-title":"Clinicopathological features of multiple mononeuropathy associated with systemic lupus erythematosus: a multicenter study","volume":"264","author":"Rivi\u00e8re","year":"2017","journal-title":"J Neurol"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.12.004_bib0086","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/0961203313512540","article-title":"Mortality in neuropsychiatric systemic lupus erythematosus (NPSLE)","volume":"23","author":"Zirkzee","year":"2014","journal-title":"Lupus"},{"issue":"6","key":"10.1016\/j.semarthrit.2020.12.004_bib0087","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1136\/ard.2007.077594","article-title":"Seizures in patients with systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA LIV)","volume":"67","author":"Andrade","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.semarthrit.2020.12.004_bib0088","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.3899\/jrheum.101088","article-title":"Prognostic indicators of hospitalized patients with systemic lupus erythematosus: a large retrospective multicenter study in China","volume":"38","author":"Feng","year":"2011","journal-title":"J Rheumatol"},{"issue":"9","key":"10.1016\/j.semarthrit.2020.12.004_bib0089","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1136\/annrheumdis-2011-201089","article-title":"Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study","volume":"71","author":"Hanly","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.semarthrit.2020.12.004_bib0090","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1177\/0961203309104392","article-title":"Time to neuropsychiatric damage occurrence in LUMINA (LXVI): a multi-ethnic lupus cohort","volume":"18","author":"Gonz\u00e1lez","year":"2009","journal-title":"Lupus"},{"issue":"4","key":"10.1016\/j.semarthrit.2020.12.004_bib0091","first-page":"766","article-title":"Neuropsychiatric manifestations and their clinical associations in southern Chinese patients with systemic lupus erythematosus","volume":"28","author":"Mok","year":"2001","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2020.12.004_bib0092","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/01.md.0000231955.08350.1b","article-title":"Neuropsychiatric damage in Southern Chinese patients with systemic lupus erythematosus","volume":"85","author":"Mok","year":"2006","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.12.004_bib0093","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11926-010-0141-y","article-title":"Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients","volume":"13","author":"Petri","year":"2011","journal-title":"Curr Rheumatol Rep"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.12.004_bib0094","first-page":"172","article-title":"Immunoablative cyclophosphamide for refractory lupus-related neuromyelitis optica","volume":"35","author":"Mok","year":"2008","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.12.004_bib0095","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1046\/j.1563-2571.2002.01040.x","article-title":"Immunoadsorption therapy (therasorb) in patients with severe lupus erythematosus","volume":"29","author":"Graninger","year":"2002","journal-title":"Acta Med Austriaca"},{"issue":"5","key":"10.1016\/j.semarthrit.2020.12.004_bib0096","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s10067-010-1591-3","article-title":"Improvement of irregularity of brain vessel walls in systemic lupus erythematosus by tacrolimus","volume":"30","author":"Kizu","year":"2011","journal-title":"Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2020.12.004_bib0097","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1159\/000237105","article-title":"Multimodal therapy in life-threatening cerebral lupus erythematosus: the benefit of cerebrospinal fluid pheresis","volume":"107","author":"Pfausler","year":"1995","journal-title":"Int Arch Allergy Immunol"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.12.004_bib0098","first-page":"61","article-title":"Filtration of cerebrospinal fluid for acute demyelinating neuropathy in systemic lupus erythematosus","volume":"19","author":"Stahl","year":"2000","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.12.004_bib0099","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1191\/0961203302lu137cr","article-title":"Sustained normalization of cerebral blood-flow after iloprost therapy in a patient with neuropsychiatric systemic lupus erythematosus","volume":"11","author":"Mathieu","year":"2002","journal-title":"Lupus"},{"key":"10.1016\/j.semarthrit.2020.12.004_bib0100","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jaut.2016.04.005","article-title":"Autoimmunity, neuroinflammation, pathogen load: a decisive crosstalk in neuropsychiatric SLE","volume":"74","author":"Jeltsch-David","year":"2016","journal-title":"J Autoimmun"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.12.004_bib0101","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/art.40591","article-title":"Review: nervous System Disease in Systemic Lupus Erythematosus: current Status and Future Directions","volume":"71","author":"Hanly","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.12.004_bib0102","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jaut.2016.06.013","article-title":"The diagnosis and clinical management of the neuropsychiatric manifestations of lupus","volume":"74","author":"Govoni","year":"2016","journal-title":"J Autoimmun"},{"issue":"12","key":"10.1016\/j.semarthrit.2020.12.004_bib0103","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1590\/0004-282x20160150","article-title":"Neuropsychiatric Lupus in clinical practice","volume":"74","author":"Alessi","year":"2016","journal-title":"Arq Neuropsiquiatr"},{"issue":"4","key":"10.1016\/j.semarthrit.2020.12.004_bib0104","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s40265-015-0534-3","article-title":"Management of Neuropsychiatric Systemic Lupus Erythematosus: current Approaches and Future Perspectives","volume":"76","author":"Magro-Checa","year":"2016","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.12.004_bib0105","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1586\/17512433.2016.1111137","article-title":"Pharmacologic management of neuropsychiatric lupus","volume":"9","author":"Kivity","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.semarthrit.2020.12.004_bib0106","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nrrheum.2014.15","article-title":"Diagnosis and management of neuropsychiatric SLE","volume":"10","author":"Hanly","year":"2014","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2020.12.004_bib0107","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nrrheum.2013.157","article-title":"Pragmatic approaches to therapy for systemic lupus erythematosus","volume":"10","author":"Xiong","year":"2014","journal-title":"Nat Rev Rheumatol"},{"issue":"9","key":"10.1016\/j.semarthrit.2020.12.004_bib0108","doi-asserted-by":"crossref","first-page":"721","DOI":"10.2165\/11591670-000000000-00000","article-title":"Neuropsychiatric manifestations in systemic lupus erythematosus: epidemiology, pathophysiology and management","volume":"25","author":"Postal","year":"2011","journal-title":"CNS Drugs"},{"issue":"12","key":"10.1016\/j.semarthrit.2020.12.004_bib0109","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1177\/0961203310374338","article-title":"Neuropsychiatric lupus: clinical challenges, brain-reactive autoantibodies and treatment strategies","volume":"19","author":"Fong","year":"2010","journal-title":"Lupus"},{"issue":"6","key":"10.1016\/j.semarthrit.2020.12.004_bib0110","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nrrheum.2010.62","article-title":"Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations","volume":"6","author":"Bertsias","year":"2010","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.12.004_bib0111","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/jnnp.2009.200071","article-title":"Neurolupus","volume":"10","author":"Joseph","year":"2010","journal-title":"Pract Neurol"},{"issue":"5","key":"10.1016\/j.semarthrit.2020.12.004_bib0112","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.berh.2005.04.003","article-title":"Management of neuropsychiatric lupus","volume":"19","author":"Hanly","year":"2005","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"12","key":"10.1016\/j.semarthrit.2020.12.004_bib0113","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1191\/0961203303lu505oa","article-title":"Central nervous system lupus: a clinical approach to therapy","volume":"12","author":"Sanna","year":"2003","journal-title":"Lupus"},{"issue":"13","key":"10.1016\/j.semarthrit.2020.12.004_bib0114","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.2174\/138161208799316401","article-title":"Neuropsychiatric involvement in systemic lupus erythematosus: current therapeutic approach","volume":"14","author":"Sanna","year":"2008","journal-title":"Curr Pharm Des"},{"issue":"2","key":"10.1016\/j.semarthrit.2020.12.004_bib0115","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1053\/berh.2001.0223","article-title":"Diagnosis and management of patients with neuropsychiatric systemic lupus erythematosus (NPSLE)","volume":"16","author":"Hermosillo-Romo","year":"2002","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2020.12.004_bib0116","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.rdc.2017.06.003","article-title":"Central nervous system manifestations of systemic lupus erythematosus","volume":"43","author":"Jafri","year":"2017","journal-title":"Rheum Dis Clin North Am"},{"issue":"5","key":"10.1016\/j.semarthrit.2020.12.004_bib0117","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/1756-185X.12337","article-title":"Neuro-ophthalmologic manifestations of systemic lupus erythematosus: a systematic review","volume":"17","author":"Man","year":"2014","journal-title":"Int J Rheum Dis"},{"issue":"3","key":"10.1016\/j.semarthrit.2020.12.004_bib0118","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.autrev.2017.01.011","article-title":"Demyelinating syndrome in SLE encompasses different subtypes: do we need new classification criteria? Pooled results from systematic literature review and monocentric cohort analysis","volume":"16","author":"Piga","year":"2017","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10.1016\/j.semarthrit.2020.12.004_bib0119","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/j.1468-1331.2010.03208.x","article-title":"Acute transverse myelitis and antiphospholipid antibodies in lupus. No evidence for anticoagulation","volume":"18","author":"Katsiari","year":"2011","journal-title":"Eur J Neurol"},{"issue":"9","key":"10.1016\/j.semarthrit.2020.12.004_bib0120","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1631\/jzus.B1200057","article-title":"Efficacy and safety of rituximab therapy for systemic lupus erythematosus: a systematic review and meta-analysis","volume":"13","author":"Lan","year":"2012","journal-title":"J Zhejiang Univ Sci B"},{"issue":"7","key":"10.1016\/j.semarthrit.2020.12.004_bib0121","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s10067-010-1387-5","article-title":"Off-label use of rituximab in systemic lupus erythematosus: a systematic review","volume":"29","author":"Murray","year":"2010","journal-title":"Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2020.12.004_bib0122","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.semarthrit.2014.04.002","article-title":"Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review","volume":"44","author":"Cobo-Ib\u00e1\u00f1ez","year":"2014","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.semarthrit.2020.12.004_bib0123","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.semarthrit.2011.06.004","article-title":"Rituximab therapy in refractory neuropsychiatric lupus: current clinical evidence","volume":"41","author":"Narv\u00e1ez","year":"2011","journal-title":"Semin Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.semarthrit.2020.12.004_bib0124","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1177\/0961203309106174","article-title":"Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases","volume":"18","author":"Ramos-Casals","year":"2009","journal-title":"Lupus"},{"issue":"2","key":"10.1016\/j.semarthrit.2020.12.004_bib0125","article-title":"Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus","author":"Fernandes Mo\u00e7a Trevisani","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"10.1016\/j.semarthrit.2020.12.004_bib0126","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/nm1101-1189","article-title":"A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus","volume":"7","author":"DeGiorgio","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.semarthrit.2020.12.004_bib0127","doi-asserted-by":"crossref","first-page":"532","DOI":"10.12659\/MSM.912389","article-title":"Anti-N-methyl-D-aspartic acid receptor 2 (Anti-NR2) antibody in neuropsychiatric lupus serum damages the blood-brain barrier and enters the brain","volume":"25","author":"Wang","year":"2019","journal-title":"Med Sci Monit"},{"issue":"1\u20132","key":"10.1016\/j.semarthrit.2020.12.004_bib0128","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jneuroim.2014.04.003","article-title":"Antibody-specific behavioral effects: intracerebroventricular injection of antiphospholipid antibodies induces hyperactive behavior while anti-ribosomal-P antibodies induces depression and smell deficits in mice","volume":"272","author":"Katzav","year":"2014","journal-title":"J Neuroimmunol"},{"issue":"6","key":"10.1016\/j.semarthrit.2020.12.004_bib0129","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/art.39081","article-title":"Pathogenicity of lupus anti-ribosomal P antibodies: role of cross-reacting neuronal surface P antigen in glutamatergic transmission and plasticity in a mouse model","volume":"67","author":"Segovia-Miranda","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"10.1016\/j.semarthrit.2020.12.004_bib0130","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1136\/ard.2004.029280","article-title":"Autoantibodies to a NR2A peptide of the glutamate\/NMDA receptor in sera of patients with systemic lupus erythematosus","volume":"64","author":"Husebye","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.12.004_bib0131","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/art.21539","article-title":"Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis","volume":"54","author":"Karassa","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.semarthrit.2020.12.004_bib0132","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.autrev.2016.07.009","article-title":"The role of B cells and autoantibodies in neuropsychiatric lupus","volume":"15","author":"Wen","year":"2016","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.12.004_bib0133","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12974-016-0537-3","article-title":"B cell and\/or autoantibody deficiency do not prevent neuropsychiatric disease in murine systemic lupus erythematosus","volume":"13","author":"Wen","year":"2016","journal-title":"J Neuroinflammation"},{"issue":"8","key":"10.1016\/j.semarthrit.2020.12.004_bib0134","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/nrrheum.2017.109","article-title":"Systemic lupus erythematosus: IFN drives synapse loss via microglia","volume":"13","author":"McHugh","year":"2017","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2020.12.004_bib0135","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of Anifrolumab in Active Systemic Lupus Erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.semarthrit.2020.12.004_bib0136","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1056\/NEJM199205213262101","article-title":"A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group","volume":"326","author":"Lewis","year":"1992","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.semarthrit.2020.12.004_bib0137","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/jca.10020","article-title":"Synchronised therapy and high-dose cyclophosphamide in proliferative lupus nephritis","volume":"17","author":"Danieli","year":"2002","journal-title":"J Clin Apher"},{"issue":"4","key":"10.1016\/j.semarthrit.2020.12.004_bib0138","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/jca.21408","article-title":"Therapeutic effect of double-filtration plasmapheresis combined with methylprednisolone to treat diffuse proliferative lupus nephritis","volume":"31","author":"Li","year":"2016","journal-title":"J Clin Apher"},{"issue":"4","key":"10.1016\/j.semarthrit.2020.12.004_bib0139","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/(SICI)1098-1101(1998)13:4<163::AID-JCA4>3.0.CO;2-1","article-title":"Randomized controlled trial of pulse\/synchronization cyclophosphamide\/apheresis for proliferative lupus nephritis","volume":"13","author":"Wallace","year":"1998","journal-title":"J Clin Apher"},{"issue":"2","key":"10.1016\/j.semarthrit.2020.12.004_bib0140","doi-asserted-by":"crossref","first-page":"108","DOI":"10.5414\/CNP57108","article-title":"Comparative effects of plasmapheresis and intravenous cyclophosphamide on urinary podocyte excretion in patients with proliferative Lupus nephritis","volume":"57","author":"Nakamura","year":"2002","journal-title":"Clin Nephrol"},{"issue":"5","key":"10.1016\/j.semarthrit.2020.12.004_bib0141","first-page":"307","article-title":"Therapy of lupus nephritis. A two-year prospective study","volume":"145","author":"Doria","year":"1994","journal-title":"Ann Med Interne (Paris)"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.12.004_bib0142","first-page":"34","article-title":"Transverse myelitis: a manifestation of systemic lupus erythematosus strongly associated with antiphospholipid antibodies","volume":"17","author":"Lavalle","year":"1990","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2020.12.004_bib0143","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1136\/ard.2010.138792","article-title":"SF-36 summary and subscale scores are reliable outcomes of neuropsychiatric events in systemic lupus erythematosus","volume":"70","author":"Hanly","year":"2011","journal-title":"Ann Rheum Dis"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017220302857?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017220302857?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T14:23:38Z","timestamp":1777472618000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017220302857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":143,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0049017220302857"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2020.12.004","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of inflammatory neurologic and psychiatric manifestations of systemic lupus erythematosus: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2020.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}